Major Players profiled in the Psoriatic Arthritis Market report incorporate: F. Hoffmann-La Roche Ltd,
Abbott Laboratories, Merck & Co, Inc., Pfizer, Inc., Novartis International AG, Johnson & Johnson, and
Amgen, Inc.
Latest Industry News
1 Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ®
(tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of
active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been
intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.1 XELJANZ is the first and
only oral Janus kinase (JAK) inhibitor to be approved in the European Union (EU) for the treatment of
adults with active PsA. In 2017, XELJANZ in combination with MTX was approved in the EU for the
treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded
inadequately to, or who are intolerant to one or more DMARDs.
“People living with psoriatic arthritis may experience a variety of symptoms, making the condition
particularly difficult to diagnose and treat,”said Angela Lukin, Regional President, Inflammation and
Immunology, Pfizer. “Psoriatic arthritis, a chronic inflammatory condition which affects between 1.5 and
3 million people in Europe, causes joint pain and swelling that can eventually lead to permanent joint
damage if not diagnosed and treated sufficiently early on,” said Frank Behrens, Rheumatology at Goethe
University and Fraunhofer IME-Translational Medicine & Pharmacology, Frankfurt, Germany.
2 Novartis announced today new data in 441 Chinese patients with moderate to severe plaque psoriasis
from a Phase III study investigating the efficacy and safety of Cosentyx (secukinumab). The data, part of
a broader ongoing 52 week Phase III study in 543 patients, show 97.7% of patients treated with
Cosentyx 300mg achieved PASI 75 and 80.9% achieved PASI 90 by week 12, with 87% of patients
reaching PASI 90 by week 16. In patients treated with Cosentyx 150mg, 87.8% achieved PASI 75 and
66.4% achieved PASI 90 at week 12.
Request a Discount on standard prices of this premium report @
https://www.businessindustryreports.com/check-discount/162977 .
Region segment: This report is segmented into several key regions, with sales, revenue, market share
(%) and growth Rate (%) of Psoriatic Arthritis in these regions, from 2014 to 2023 (forecast), covering:
North America, Europe, Asia Pacific, Middle East & Africa and South America.
Significant points in table of contents: Market Definition, Market Overview, Business Introduction,
Segmentation (Region Level), Segmentation (Type Level), Segmentation (Industry Level), Segmentation
(Channel Level), Market Forecast Year, Segmentation Type, Segmentation Industry, Market Cost
Analysis, and Conclusion.
Report contents include
1 Analysis of the Psoriatic Arthritis Market including revenues, future growth, market outlook